RIBOMIC Inc.

Overview

Overview

RIBOMIC Inc. (Tokyo Stock Exchange: 4591) is a Tokyo-based biotechnology company specializing in RNA therapeutics and RNA aptamer technology. Founded in 2005, the company focuses on developing novel nucleic acid-based therapeutics using its proprietary RNA aptamer platform, positioning itself as a leader in the emerging RNA aptamer therapeutics field in Japan["@ribomic"].

RIBOMIC operates as a clinical-stage biotechnology company with a focus on developing RNA aptamers—single-stranded DNA or RNA molecules that can bind specifically to target proteins—for the treatment of ocular diseases and central nervous system disorders. The company's proprietary platform enables the systematic selection and optimization of high-affinity RNA aptamers with drug-like properties.

Company Profile

| Attribute | Details |
|-----------|---------|
| Founded | 2005 |
| Headquarters | Tokyo, Japan |
| Stock Symbol | TSE: 4591 (Standard Market) |
| Market Cap | ¥3-5 billion (~$20-35M USD) |
| Employees | ~50 |
| CEO | Dr. Tomohiro Kanda |
| Focus Areas | RNA aptamers, ocular diseases, CNS disorders |

History and Development

Company Formation and Early Years (2005-2012)

RIBOMIC was established in 2005 as a spinout from academic research in RNA aptamer technology:

2005: Company founded in Tokyo, based on SELEX (Systematic Evolution of Ligands by EXponential enrichment) technology developed at Japanese academic institutions.

2008: Established proprietary RNA aptamer selection platform with improved affinity and stability characteristics.

2010: RBM-007 program initiated for age-related macular degeneration (AMD).

2012: Listed on the Tokyo Stock Exchange (TSE Mothers market), raising capital for clinical development.

Growth and Clinical Development (2013-2020)

2014: Moved to TSE Standard market from Mothers market, reflecting increased market capitalization.

2016: Initiated Phase 1/2 clinical trial for RBM-007 in wet AMD in Japan.

2018: Completed Phase 1/2 study demonstrating safety and preliminary efficacy.

2020: RBM-007 received orphan drug designation from Japanese regulatory authorities.

Recent Developments (2021-Present)

2021: Expanded clinical development to additional ocular indications.

2022: Strategic partnership discussions with major pharmaceutical companies for RBM-007.

2023: Continued Phase 2 development of RBM-007; exploration of CNS applications.

Technology Platform

RNA Aptamer Technology

RIBOMIC's core technology is the RNA aptamer platform—a sophisticated drug discovery method that enables the systematic selection and development of RNA molecules capable of binding specifically to target proteins[@rna2017].

Advantages over antibodies:

| Feature | RNA Aptamers | Antibodies |
|---------|--------------|------------|
| Size | 5-15 kDa | 150 kDa |
| Manufacturing | Chemical synthesis | Biological production |
| Stability | High (chemical stability) | Moderate (proteolytic degradation) |
| Immunogenicity | Low | Potential for immune response |
| Tissue Penetration | Better (smaller size) | Limited |
| Cost | Lower | Higher |

Platform Capabilities

Proprietary Assets

• RNA Aptamer Library: Diverse collection of high-quality aptamers
• Selection Protocols: Optimized SELEX methodologies
• Chemical Modifications: Patented stabilization technologies
• Analytical Methods: Quality control and characterization

Product Pipeline

Clinical Programs

| Drug | Target | Indication | Development Stage | Status |
|------|--------|------------|-------------------|--------|
| RBM-007 | FGF2 (Fibroblast Growth Factor 2) | Wet AMD | Phase 2 | Active |
| RBM-007 | FGF2 | Diabetic Macular Edema | Preclinical | Research |
| RBM-007 | FGF2 | Ocular fibrosis | Research | Preclinical |

RBM-007 (Lead Program)

RBM-007 is an anti-FGF2 RNA aptamer being developed for multiple ocular diseases:

Mechanism of Action:

• Binds to FGF2 with high affinity and specificity
• Inhibits FGF2-mediated signaling in ocular tissues
• Reduces neovascularization and fibrosis in retinal diseases

• Phase 1/2 completed in Japan showing safety and preliminary efficacy
• Phase 2 trial ongoing in Japan
• Addresses VEGF-independent pathway (complementary to anti-VEGF therapies)

• Preclinical development
• FGF2 implicated in diabetic retinal complications

• Research stage
• FGF2 plays role in fibrotic eye diseases

Research Programs

| Program | Target | Indication | Stage |
|---------|--------|------------|-------|
| CNS aptamer program | Various | Neurodegeneration | Discovery |
| Ocular new indications | Various | Dry eye, glaucoma | Discovery |

Business Model

Licensing Strategy

RIBOMIC operates primarily through a licensing model:

Partnership Approach

The company seeks partnerships with larger pharmaceutical companies:

• Provides technology platform access
• Enables co-development of therapeutic programs
• Supports global commercialization

Revenue Model

• Research funding: From partnership agreements
• Milestone payments: Based on development achievements
• Royalty income: From commercialized products

Competitive Landscape

In RNA Therapeutics

| Company | Technology | Focus |
|---------|------------|-------|
| Ionis Pharmaceuticals | ASO, RNAe | Various diseases |
| Alnylam Pharmaceuticals | siRNA | Various diseases |
| Dicerna Pharmaceuticals | GalNAc-siRNA | Various diseases |
| RIBOMIC | RNA aptamers | Ocular, CNS |

Competitive Advantages

Challenges

• Funding constraints: Limited capital for extensive clinical trials
• Competition: Large pharma focus on different modalities
• Regulatory: Japanese-only clinical data may limit global appeal

Financial Performance

Stock Information

• TSE Listing: Standard Market (4591)
• Market Cap: ¥3-5 billion (~$20-35M USD)
• Stock Price: ~¥400-600 per share (as of 2024)

Funding History

| Year | Event | Amount |
|------|-------|--------|
| 2012 | IPO | ¥500M |
| 2018 | Secondary offering | ¥800M |
| 2021 | Partnership funding | ¥200M |

Financial Position

• Cash reserves: Sufficient for 2-3 years of operations
• R&D spending: ~¥500M annually
• Burn rate: ~¥50M per month

Research Collaborations

Academic Partnerships

• University of Tokyo: Continued RNA aptamer research collaboration
• Kyoto University: Drug delivery technology development
• Japanese research institutes: Various academic collaborations

Industry Partnerships

• Discussions with major pharma: Ongoing for RBM-007 licensing
• Drug delivery companies: Optimization of ocular formulations
• Manufacturing partners: Scale-up and production

Strategic Outlook

Growth Drivers

Challenges

• Capital constraints: Need additional funding for extensive clinical trials
• Competition: Antibody and other RNA therapeutics remain dominant
• Market size: Relatively small market for aptamer therapeutics

Future Directions

Near-Term (2024-2025):

• Complete Phase 2 trial for RBM-007 in wet AMD
• Secure partnership for RBM-007 global development
• Advance CNS program into preclinical development

• Launch RBM-007 in Japanese market (2026+)
• Expand to additional ocular indications
• Develop CNS pipeline for neurodegenerative diseases

Cross-References

Related Technology Pages

• [RNA Therapeutics](/technologies/rna-therapeutics)
• [RNA Aptamers](/technologies/rna-aptamers)
• [Gene Therapy](/technologies/gene-therapy)

Related Disease Pages

• [Age-Related Macular Degeneration](/diseases/age-related-macular-degeneration)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

Related Company Pages

• [Ionis Pharmaceuticals](/companies/ionis)
• [Alnylam Pharmaceuticals](/companies/alnylam)
• [Japanese Biotech Companies](/companies/japanese-neurodegeneration-biotech)

References

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [RNA Therapeutics](/technologies/rna-therapeutics)
• [Japanese Biotech Companies](/companies/japanese-neurodegeneration-biotech)